Indications for DART Regimen in Extremely Preterm Care
Low-dose dexamethasone therapy (<0.2 mg/kg per day) should be considered for extremely preterm infants who remain ventilator-dependent after 1-2 weeks of life and are at very high risk of developing bronchopulmonary dysplasia (BPD), specifically to facilitate extubation. 1
Primary Clinical Indication
The DART (low-dose dexamethasone) regimen is indicated for:
- Very low birth weight infants (<1000 g) or very preterm infants (<28 weeks gestation) who remain on mechanical ventilation after the first 1-2 weeks of postnatal age 1, 2
- Infants at very high risk of developing BPD who have failed to wean from ventilatory support 1
Specific Clinical Parameters
Consider DART when the infant demonstrates:
- Continued ventilator dependence beyond 10-21 days of life
- Mean airway pressure ≥8 cm H₂O and FiO₂ ≥60% (based on trial criteria) 3
- Failed previous attempts at extubation
- Progressive or evolving BPD despite maximal conventional respiratory support 1
Dosing Framework
The recommended low-dose dexamethasone regimen is <0.2 mg/kg per day, typically administered as 0.89 mg/kg total over 10 days 2. The AAP guidelines explicitly state that this low-dose approach may facilitate extubation and decrease short- and long-term adverse effects compared to higher doses 1.
Critical Safety Considerations
High-dose dexamethasone (≥0.5 mg/kg per day) is NOT recommended due to associations with neurodevelopmental impairment, including decreased hippocampal volume and altered memory formation, without additional therapeutic benefit over lower doses 1. Recent evidence suggests that multiple courses of even low-dose dexamethasone may increase risk of cerebral palsy 4, and prolonged exposure is associated with worse neurodevelopmental outcomes at 20 months 5.
Decision-Making Algorithm
When considering DART:
Timing: Initiate after the first week of life (typically 10-23 days) when infant remains ventilator-dependent 2
Risk-Benefit Assessment: Balance the severe morbidity and mortality of BPD against potential neurodevelopmental risks of steroid therapy 1
Parental Counseling: Parents must be fully informed about known short- and long-term risks and provide agreement to treatment 1
Avoid Multiple Courses: Limit to single course when possible, as repeated courses are associated with higher rates of cerebral palsy (OR 6.8) and ophthalmological problems 4
Important Caveats
- Avoid concomitant indomethacin or ibuprofen due to increased risk of intestinal perforation 1
- The evidence base remains "conflicting and inconclusive" per AAP guidelines, requiring individualized clinical judgment 1
- Low-dose dexamethasone clearly facilitates extubation (60% vs 12% success rate) and shortens intubation duration without obvious short-term complications 2
- Consider hydrocortisone as an alternative, particularly in the first 2 weeks of life in settings of prenatal inflammation, as it may have a more favorable neurodevelopmental profile 1
Contraindications to DART
Do not use in:
- Routine prevention of BPD (not indicated for prophylaxis) 1
- Infants successfully weaning from ventilatory support
- Active sepsis or uncontrolled infection
- Concurrent treatment with prostaglandin synthesis inhibitors 1
The fundamental principle is that DART should be reserved for infants facing the competing risks of severe BPD versus potential steroid-related neurodevelopmental harm, with treatment decisions made jointly with informed parents 1.